RE:RE:Price drop reason? Moreover, I am pleased to provide an update on the demand trends we are seeing within our sleep business. Despite the ongoing market speculation and reaction concerning the adoption of GLP-1 diabetes and weight loss medications, I can confidently report that our sleep segment continued to remain unaffected. Demand patterns continued to exhibit strengths in real time, and our anticipation is that this will persist well into the foreseeable future.
Recently, the largest manufacturer of sleep devices in the industry published data from a real-world study that showed a significant positive correlation between GLP-1s and PAP therapy. The findings were that patients with an OSA diagnosis and prescribe their GLP-1 are actually more likely to initiate PAP therapy and order supplies more frequently.
In addition, it is critical to stress that CPAP and BiPAP therapy remain the accepted Gold Standard of care for patients with obstructive sleep apnea.
Furthermore, we firmly believe that over 20 million Americans have OSA, but have not yet received a diagnosis, which represents a significant unrealized potential for future market expansion. As of right now, we think that rising awareness and more OSA diagnosis could lead to a rise in the overall addressable market.